We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study
Read MoreHide Full Article
Key Takeaways
AstraZeneca fell after Wainua failed to meet the primary endpoint in the phase III ATTR-CM study.
AZN and Ionis will analyze the full data set and present findings at the ESC Congress next month.
AZN's setback lifted Alnylam and BridgeBio shares as investors reassessed the ATTR-CM landscape.
Shares of AstraZeneca (AZN - Free Report) fell nearly 8% in pre-market trading today after the company announced the failure of a phase III study evaluating Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The company is co-developing this drug with Ionis Pharmaceuticals (IONS - Free Report) , whose stock also slumped 19% following the announcement.
The late-stage study, called CARDIO-TTRansform, failed to meet its primary endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events. Although the drug was well tolerated in study participants over a 140-week treatment period, adding Wainua to the standard of care did not demonstrate a statistically significant benefit compared to placebo.
The CARDIO-TTRansform study outcome comes as a surprise, as investors were expecting positive results. Wainua is already approved for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN), a condition in which misfolded transthyretin (TTR) protein deposits damage peripheral nerves.
ATTR-CM is caused by the same misfolded TTR protein but primarily affects the heart, where amyloid deposits accumulate in the heart muscle, leading to progressive CV disease. Success in ATTR-CM was expected to significantly expand Wainua's commercial opportunity, as the ATTR-CM market is considerably larger than the ATTRv-PN market.
Both companies plan to analyze the full data set to better understand the results and intend to present the findings at the European Society of Cardiology (ESC) Congress next month.
AZN Stock Performance
Shares of AstraZeneca have underperformed the industry so far this year, as seen in the chart below.
Image Source: Zacks Investment Research
Rivals Rally on AZN's Setback
Following AstraZeneca/Ionis’ update, shares of Alnylam Pharmaceuticals (ALNY - Free Report) and BridgeBio Pharma (BBIO - Free Report) rose about 18% and 11%, respectively, in pre-market trading on Thursday. With Wainua failing to meet the primary endpoint in the CARDIO-TTRansform study, AstraZeneca's entry into the ATTR-CM market now faces uncertainty. Investors appear to view the setback as strengthening the near-term competitive position of ALNY and BBIO.
BridgeBio's Attruby was approved by the FDA for ATTR-CM in 2024, while Alnylam's Amvuttra received a label expansion for the indication last year. Both companies are well positioned in the rapidly growing ATTR-CM market, where effective disease-modifying therapies remain in high demand.
While Amvuttra was initially approved for the treatment of ATTRv-PN, its label expansion into ATTR-CM significantly broadened the drug's commercial opportunity. The expanded approval helped Amvuttra achieve blockbuster status, with sales surging 138% year over year to $2.31 billion in 2025, underscoring the sizable commercial potential of the ATTR-CM market. Meanwhile, BridgeBio generated $362.4 million in Attruby sales during the drug's first full year on the market, reflecting the strong demand for therapies targeting the disease.
View the Zacks #1 Rank List
Image: Bigstock
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study
Key Takeaways
Shares of AstraZeneca (AZN - Free Report) fell nearly 8% in pre-market trading today after the company announced the failure of a phase III study evaluating Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The company is co-developing this drug with Ionis Pharmaceuticals (IONS - Free Report) , whose stock also slumped 19% following the announcement.
The late-stage study, called CARDIO-TTRansform, failed to meet its primary endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events. Although the drug was well tolerated in study participants over a 140-week treatment period, adding Wainua to the standard of care did not demonstrate a statistically significant benefit compared to placebo.
The CARDIO-TTRansform study outcome comes as a surprise, as investors were expecting positive results. Wainua is already approved for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN), a condition in which misfolded transthyretin (TTR) protein deposits damage peripheral nerves.
ATTR-CM is caused by the same misfolded TTR protein but primarily affects the heart, where amyloid deposits accumulate in the heart muscle, leading to progressive CV disease. Success in ATTR-CM was expected to significantly expand Wainua's commercial opportunity, as the ATTR-CM market is considerably larger than the ATTRv-PN market.
Both companies plan to analyze the full data set to better understand the results and intend to present the findings at the European Society of Cardiology (ESC) Congress next month.
AZN Stock Performance
Shares of AstraZeneca have underperformed the industry so far this year, as seen in the chart below.
Image Source: Zacks Investment Research
Rivals Rally on AZN's Setback
Following AstraZeneca/Ionis’ update, shares of Alnylam Pharmaceuticals (ALNY - Free Report) and BridgeBio Pharma (BBIO - Free Report) rose about 18% and 11%, respectively, in pre-market trading on Thursday. With Wainua failing to meet the primary endpoint in the CARDIO-TTRansform study, AstraZeneca's entry into the ATTR-CM market now faces uncertainty. Investors appear to view the setback as strengthening the near-term competitive position of ALNY and BBIO.
BridgeBio's Attruby was approved by the FDA for ATTR-CM in 2024, while Alnylam's Amvuttra received a label expansion for the indication last year. Both companies are well positioned in the rapidly growing ATTR-CM market, where effective disease-modifying therapies remain in high demand.
While Amvuttra was initially approved for the treatment of ATTRv-PN, its label expansion into ATTR-CM significantly broadened the drug's commercial opportunity. The expanded approval helped Amvuttra achieve blockbuster status, with sales surging 138% year over year to $2.31 billion in 2025, underscoring the sizable commercial potential of the ATTR-CM market. Meanwhile, BridgeBio generated $362.4 million in Attruby sales during the drug's first full year on the market, reflecting the strong demand for therapies targeting the disease.
AstraZeneca PLC Price
AstraZeneca PLC price | AstraZeneca PLC Quote
AZN’s Zacks Rank
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.